BRD7 and urinary bladder carcinoma: The loss of the bromodomain leads to cancer sensitivity to PARPi and CPT, while small molecules containing bromodomains, such as BRD7, occur mutations in cancer types such as bladder cancer, which may indicate that bromodomain inhibitors are effective for bladder cancer treatment.